ESMO 2023 Insights: "Results From the MEDISARC Phase II Study of Durvalumab & Tremelimumab Compared to Doxorubicin in Patients With Advanced/Metastatic Soft Tissue Sarcoma"

141 views
October 25, 2023
Comments 0
Login to view comments. Click here to Login